



DEPARTMENT OF HEALTH & HUMAN SERVICES

Rec'd 10/31/96 KT

Public Health Service

Food and Drug Administration
Rockville MD 20857

SEP 25 1996

Re: ADENOSCAN®
Docket No. 95E-0303

Stephen G. Kunin
Deputy Assistant Commissioner for
Patent Policy and Projects
U.S. Patent and Trademark Office
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, DC 20231

#39

Dear Mr. Kunin:

This is in regard to the patent term extension application for U.S. Patent No. 5,070,877 filed by Medco Research, Inc. under 35 U.S.C. § 156. The patent claims the human drug product ADENOSCAN®, New Drug Application (NDA) 20-059.

In the January 2, 1996, issue of the Federal Register (61 Fed. Reg. 73), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before July 1, 1996, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson
Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Jae H. Kim
Hopgood, Calimafde, Kalil & Judlowe
Lincoln Building
60 East 42nd Street
New York, NY 10165